• Dirk Nagorsen, Peter Kufer, Patrick A Baeuerle, and Ralf Bargou.
• Amgen Research-Munich GmbH, Staffelseestr. 2, 81477 Munich, Germany. dirk.nagorsen@amgen.com
• Pharmacol. Ther. 2012 Dec 1;136(3):334-42.

AbstractFor decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal antibodies, irradiation and/or hematopoietic stem cell transplantation are added. However, the current standard of care--particularly for patients with relapsed disease--is often not sufficient to achieve durable remissions. A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT103 or AMG 103). This bispecific antibody construct has dual specificity for CD19 and CD3 and belongs to the class of bispecific T cell engager (BiTE®) antibodies, which can potentially engage all cytotoxic T cells of a patient for redirected lysis of tumor cells. Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia.Copyright © 2012 Elsevier Inc. All rights reserved.

13 keywords...

hide…